It took only a few months for COVID-19 to effect sometimes irreversible changes on regulatory and compliance activities in the life sciences industry. The impact on regulatory workflows, clinical data management, and trial monitoring has been wildly disruptive, triggering an evolution in the way regulatory professionals do their work. It has also shined a new spotlight on the benefits that cloud technology and outsourcing can bring to regulatory compliance – particularly in times of crisis.
In partnership with IQVIA, Informa Pharma Intelligence surveyed life sciences regulatory respondents from a wide range of positions in regulatory affairs, operations, management and consulting to assess the impact of COVID-19 on regulatory processes. Read the results in the research paper to understand the impact of the pandemic and how the future has changed for regulatory compliance.